抗リウマチ薬の北米市場2020-2189

◆英語タイトル:NORTH AMERICA ANTI-RHEUMATICS MARKET FORECAST 2020-2028
◆商品コード:INK20MY240
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:北米
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe North America anti-rheumatics market is estimated to witness considerable growth and record a CAGR of 2.63% over the forecast period, 2020-2028. One of the significant factors propelling market growth is the presence of major key players such as Merck & Co., Inc, AbbVie Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc, and Pfizer, Inc augments market growth.

MARKET INSIGHTS
In order to study the growth of the North America anti-rheumatics market further, the region is segmented into the United States and Canada. In Canada, as per the Arthritis Society, 300,000 Canadians suffer from rheumatoid arthritis. Hence, the prevalence of this medical condition leads to an increased demand for anti-rheumatics in the region. Moreover, a rise in the elderly population is another significant factor in influencing the market growth. According to the statistics of the Canadian government, in 2014, the number of Canadians aged 65 or older was 6 million, representing 15.6% of Canada’s population. By 2030, the number of senior citizens will be over 9.5 million, which will represent 23% of Canadians. Moreover, the average life expectancy of men will rise from 80 to 82.9 and of women from 84.2 to 86.2 by 2036, which is expected to drive the market as the older population is more prone to rheumatoid arthritis.

COMPETITIVE INSIGHTS
Bio-Rad Laboratories Inc, Abbott Laboratories, Johnson & Johnson, AbbVie Inc, Merck & Co Inc, Pfizer Inc, etc. are some of the prominent companies operating in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. RISING GERIATRIC POPULATION
3.2.2. SURGE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS DISEASE
3.2.3. GROWING HEALTHCARE EXPENDITURE
3.3. KEY RESTRAINTS
3.3.1. PATENT EXPIRATIONS
3.3.2. LACK OF REGULATORY GUIDELINES FOR BIOSIMILARS WILL DELAY THEIR AVAILABILITY IN SOME REGIONS
3.3.3. LESS EXPENSIVE ALTERNATIVES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. ETIOLOGY OF RHEUMATOID ARTHRITIS (RA)
4.3. SYMPTOMS OF RHEUMATOID ARTHRITIS
4.4. RISK FACTORS ASSOCIATED WITH RHEUMATOID ARTHRITIS
4.5. OPPORTUNITY MATRIX
4.6. VENDOR LANDSCAPE
4.7. KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1. PRESCRIPTION-BASED DRUGS
5.2. OVER-THE-COUNTER DRUGS
6. MARKET BY DRUG CLASS
6.1. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
6.2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
6.3. CORTICOSTEROIDS
6.4. URIC ACID DRUGS
6.5. OTHER DRUG CLASS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ABBVIE INC
8.3. AMGEN INC
8.4. BECTON, DICKINSON & COMPANY (BD)
8.5. BIO-RAD LABORATORIES INC
8.6. BRISTOL-MYERS SQUIBB COMPANY
8.7. ELI LILLY & COMPANY
8.8. LUPIN LIMITED
8.9. F. HOFFMANN-LA ROCHE
8.10. JOHNSON & JOHNSON
8.11. MERCK & CO INC
8.12. NOVARTIS AG
8.13. PERKINELMER
8.14. PFIZER INC
8.15. UCB



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗リウマチ薬の北米市場2020-2189]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆